Pfizer Inc. (NYSE:PFE) – Equities researchers at SVB Leerink raised their FY2020 earnings per share (EPS) estimates for Pfizer in a report launched on Tuesday, November 24th. SVB Leerink analyst G. Porges now forecasts that the biopharmaceutical firm will put up earnings of $2.88 per share for the yr, up from their prior forecast of $2.85. SVB Leerink presently has a “Market Carry out” ranking and a $43.00 goal price on the stock. SVB Leerink additionally issued estimates for Pfizer‘s This autumn 2020 earnings at $0.57 EPS, FY2021 earnings at $2.91 EPS, FY2022 earnings at $2.73 EPS and FY2023 earnings at $2.82 EPS.
Different equities analysts have additionally lately issued reviews in regards to the stock. Sanford C. Bernstein began protection on shares of Pfizer in a analysis observe on Tuesday, November 10th. They issued a “market carry out” ranking and a $42.00 goal price for the corporate. Truist started protection on shares of Pfizer in a report on Friday, October 23rd. They issued a “purchase” ranking and a $42.00 price goal for the corporate. JPMorgan Chase & Co. set a $36.00 price goal on shares of Pfizer and gave the stock a “impartial” ranking in a report on Monday, November ninth. Berenberg Bank started protection on shares of Pfizer in a report on Tuesday, September 29th. They issued a “maintain” ranking and a $38.00 price goal for the corporate. Lastly, Royal Bank of Canada set a $43.00 price goal on shares of Pfizer and gave the stock a “purchase” ranking in a report on Friday, October 16th. One analyst has rated the stock with a promote ranking, ten have issued a maintain ranking and 5 have assigned a purchase ranking to the corporate’s stock. The stock presently has a consensus ranking of “Maintain” and a median goal price of $39.80.
PFE opened at $36.53 on Thursday. The corporate has a debt-to-equity ratio of 0.78, a present ratio of 1.42 and a fast ratio of 1.16. The agency has a fifty day shifting common price of $37.04 and a 200 day shifting common price of $36.58. Pfizer has a 1 yr low of $27.88 and a 1 yr excessive of $41.99. The stock has a market cap of $203.05 billion, a P/E ratio of 14.50, a P/E/G ratio of three.10 and a beta of 0.66. Pfizer (NYSE:PFE) final posted its earnings outcomes on Tuesday, October 27th. The biopharmaceutical firm reported $0.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.01. Pfizer had a internet margin of 28.80% and a return on fairness of 25.11%. The agency had income of $12.13 billion in the course of the quarter, in comparison with analysts’ expectations of $12.30 billion. Throughout the identical interval within the earlier yr, the enterprise posted $0.75 EPS. The enterprise’s income was down 4.3% in comparison with the identical quarter final yr.
The corporate additionally lately disclosed a quarterly dividend, which will likely be paid on Tuesday, December 1st. Traders of document on Friday, November sixth will likely be issued a $0.38 dividend. This represents a $1.52 dividend on an annualized foundation and a dividend yield of 4.16%. The ex-dividend date of this dividend is Thursday, November fifth. Pfizer‘s dividend payout ratio is presently 51.53%.
In different information, main shareholder Pfizer Inc acquired 1,200,00Zero shares of the corporate’s stock in a transaction that occurred on Tuesday, October 27th. The stock was bought at a median price of $10.00 per share, with a complete value of $12,000,000.00. Following the completion of the acquisition, the insider now owns 27,349,211 shares of the corporate’s stock, valued at roughly $273,492,110. The transaction was disclosed in a submitting with the Securities & Change Fee, which is accessible via this hyperlink. Company insiders personal 0.08% of the corporate’s stock.
A number of institutional buyers and hedge funds have lately modified their holdings of the corporate. NuWave Funding Administration LLC raised its place in shares of Pfizer by 439.7% within the third quarter. NuWave Funding Administration LLC now owns 1,468 shares of the biopharmaceutical firm’s stock valued at $54,00Zero after buying an extra 1,196 shares within the final quarter. Sumitomo Mitsui Monetary Group Inc. purchased a brand new stake in shares of Pfizer within the third quarter valued at roughly $59,000. Lenox Wealth Administration Inc. elevated its holdings in shares of Pfizer by 22.5% within the 2nd quarter. Lenox Wealth Administration Inc. now owns 2,029 shares of the biopharmaceutical firm’s stock valued at $66,00Zero after buying an extra 372 shares over the past quarter. Demars Monetary Group LLC purchased a brand new stake in shares of Pfizer within the 2nd quarter valued at roughly $75,000. Lastly, RMR Wealth Builders purchased a brand new stake in shares of Pfizer within the 2nd quarter valued at roughly $91,000. 69.08% of the stock is presently owned by institutional buyers and hedge funds.
Pfizer Firm Profile
Pfizer Inc develops, manufactures, and sells healthcare merchandise worldwide. It gives medicines and vaccines in numerous therapeutic areas, together with cardiovascular metabolic and ache beneath the Eliquis, Chantix/Champix, and Premarin household manufacturers; biologics, small molecules, immunotherapies, and biosimilars beneath the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi manufacturers; and sterile injectable and anti-infective medicines beneath the Sulperazon, Medrol, Vfend, and Zithromax manufacturers.
Featured Story: Diversification
This prompt information alert was generated by narrative science expertise and monetary knowledge from MarketBeat as a way to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial workforce previous to publication. Please ship any questions or feedback about this story to [email protected]